Tradestie Institutional Equity Comparison Engine
SLS vs VIVS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SLS Overall Edge
SLS Captures Institutional Edge (3โ0 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to SELLAS Life Sciences Group, Inc. Common Stock (SLS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, SLS trades at N/M Forward P/E with 0.0% operating margin (-82.5% YoY revenue) versus VIVS at N/M Forward P/E and -10117.0% operating margin (-51.4% YoY). In options structure, SLS sits in CONSOLIDATION (16th %ile IV; Dealer Gamma Walls on Pro) against VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
SLS N/M vs VIVS N/M Fwd P/E
Growth & Margin Winner
SLS
Op Margin 0.0% vs -10117.0% ยท YoY -82.5% vs -51.4%
Momentum & Technical Winner
SLS
1Y +834.6% vs -87.0% ยท 52W Pos 57% vs 5%
Options & Structure Winner
SLS
CONSOLIDATION (16th %ile IV) vs BREAKDOWN (N/A IV)
SLS
NASDAQ
SELLAS Life Sciences Group, Inc. Common Stock
Pharmaceutical Preparations
$14.86
-17.21% 1D
Market Cap
$3.7B
1M Return
+22.41%
1Y Return
+834.59%
Forward P/E
N/M
Unified AI Score
39.3 / 100
SELL
Tech 50.0
Fund 37.0
Flow 68.0
Mom 48.9
VIVS
NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap
$2.4M
1M Return
+64.69%
1Y Return
-86.99%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 5.0
Fund 38.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SLS +834.59%
VIVS -86.99%
Spread: +921.58 pp (SLS Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SLS Revenue | VIVS Revenue | SLS Op. Margin | VIVS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | N/A | $0M | N/A | -882.4% | VIVS |
| FY2020 | $0M | $0M | -893.8% | -977.9% | SLS |
| FY2021 | $10M | N/A | -332.8% | N/A | SLS |
| FY2022 | $0M | $0M | -4195.0% | -765.3% | VIVS |
| FY2023 | N/A | $0M | N/A | -4792.2% | VIVS |
| FY2024 | N/A | $0M | N/A | -13840.4% | VIVS |
| FY2025 | N/A | $0M | N/A | -8761.1% | VIVS |
| FY2026 | N/A | $0M | N/A | -8768.7% | VIVS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SLS | VIVS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.7B | $2.4M | Larger Scale | SLS |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -82.5% | -51.4% | Higher Growth | VIVS |
| Operating Margin (TTM) Profitability | 0.0% | -10117.0% | Higher Margin | SLS |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -40.3% | -343.1% | Higher ROE | SLS |
| 52-Week Range Position Momentum | 57% ($1โ$25) | 5% ($0โ$3) | Stronger Trend | SLS |
| Beta / 30D Volatility Risk Regime | 1.84ฮฒ ยท 551% Vol | 0.83ฮฒ ยท 480% Vol | Lower Realized Risk | VIVS |
| Unified Institutional Score Composite Signal | 39.3 / 100 (SELL) | 36.8 / 100 (SELL) | Higher Composite | SLS |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SLS vs VIVS Buy Guide
SLS
CONSOLIDATION
101d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
16th %ile
IV Regime
Compressed (<25th %ile)
VIVS
BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SLS nor VIVS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.